However, ponatinib and venetoclax combination may lose efficacy when BCR::ABL1 activity is not adequately suppressed by ponatinib, e.g, in the case of CML resistance associated with BCR::ABL1 T315I-inclusive compound mutations [14, 15]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.